# Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

> **NCT01858961** · PHASE3 · WITHDRAWN · sponsor: **Boehringer Ingelheim**

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** BI 201335
- **DRUG:** ribavirin
- **DRUG:** BI 207127
- **DRUG:** Telaprevir
- **DRUG:** ribavirin
- **DRUG:** Pegylated Interferon

## Key facts

- **NCT ID:** NCT01858961
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-05
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01858961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01858961, "Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT01858961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*